Shandro Benjamin M, Chen Joshua, Ritehnia Jennifer, Poullis Andrew
Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust, London SW17 0QT, United Kingdom.
World J Clin Cases. 2021 Nov 6;9(31):9469-9480. doi: 10.12998/wjcc.v9.i31.9469.
Pancreatic exocrine insufficiency (PEI) is said to be associated with numerous conditions both within and outside the gastrointestinal (GI) system. The majority of research has been concerned with conditions that reduce the volume of functioning pancreatic tissue or prevent adequate drainage to the small bowel, such as chronic pancreatitis, cystic fibrosis, pancreatic cancer and pancreatic resection. However, the evidence base supporting an association with extra-pancreatic conditions, such as coeliac disease, diabetes mellitus and congestive cardiac failure, is heterogeneous.
To strengthen the evidence base by studying all previously reported associations with PEI in a large cohort of outpatients.
A single-centre retrospective study was performed. General gastroenterology outpatients tested for PEI with faecal elastase-1 (FE1) were identified and information retrieved from the electronic patient record. PEI was defined as FE1 < 200 μg/g. Patients already taking pancreatic enzyme replacement therapy were excluded. Multiple imputation was used to handle missing data. Univariable logistic regression was used to study which presenting symptoms predicted PEI. Multivariable logistic regression was used to explore the relationship between all previously reported associations and PEI.
Of 1027 patients were included. 182 patients (17.7%) were diagnosed with PEI. Steatorrhoea [odds ratios (OR): 2.51, 95% confidence intervals (CI): 1.58-3.98] and weight loss (OR: 1.49, 95%CI: 1.08-2.06) were the only presenting symptoms that predicted PEI. Chronic pancreatitis (OR: 7.98, 95%CI: 3.95-16.15), pancreatic cancer (OR: 6.58, 95%CI: 1.67-25.98), upper GI surgery (OR: 2.62, 95%CI: 1.32-5.19), type 2 diabetes (OR: 1.84, 95%CI: 1.18-2.87), proton pump inhibitor therapy (OR: 1.87, 95%CI: 1.25-2.80) and Asian ethnicity (OR: 2.11, 95%CI: 1.30-3.42) were significantly associated with PEI in the multivariable analysis. None of the other historically reported associations with PEI were significant after adjustment for the other variables included in our multivariable analysis.
PEI is common in patients with chronic pancreatitis, pancreatic cancer, upper GI surgery and type 2 diabetes. Proton pump inhibitor therapy may also be associated with PEI or a false positive FE1.
胰腺外分泌功能不全(PEI)据说与胃肠道(GI)系统内外的多种病症相关。大多数研究关注的是减少功能性胰腺组织体积或阻碍向小肠充分引流的病症,如慢性胰腺炎、囊性纤维化、胰腺癌和胰腺切除术。然而,支持其与腹腔疾病、糖尿病和充血性心力衰竭等胰腺外病症相关的证据基础并不一致。
通过在一大群门诊患者中研究所有先前报道的与PEI的关联来加强证据基础。
进行了一项单中心回顾性研究。确定了用粪便弹性蛋白酶-1(FE1)检测PEI的普通胃肠病门诊患者,并从电子病历中检索信息。PEI定义为FE1<200μg/g。已接受胰腺酶替代疗法的患者被排除。采用多重填补法处理缺失数据。单变量逻辑回归用于研究哪些症状预示着PEI。多变量逻辑回归用于探讨所有先前报道的关联与PEI之间的关系。
共纳入1027例患者。182例患者(17.7%)被诊断为PEI。脂肪泻[比值比(OR):2.51,95%置信区间(CI):1.58 - 3.98]和体重减轻(OR:1.49,95%CI:1.08 - 2.06)是仅有的预示PEI的症状。慢性胰腺炎(OR:7.98,95%CI:3.95 - 16.15)、胰腺癌(OR:6.58,95%CI:1.67 - 25.98)、上消化道手术(OR:2.62,95%CI:1.32 - 5.19)、2型糖尿病(OR:1.84,95%CI:1.18 - 2.87)、质子泵抑制剂治疗(OR:1.87,95%CI:1.25 - 2.80)和亚洲人种(OR:2.11,95%CI:1.30 - 3.42)在多变量分析中与PEI显著相关。在对我们多变量分析中纳入的其他变量进行调整后,其他历史上报道的与PEI的关联均无显著性。
PEI在慢性胰腺炎、胰腺癌、上消化道手术和2型糖尿病患者中很常见。质子泵抑制剂治疗也可能与PEI或FE1假阳性有关。